Modest Waning of Influenza Vaccine Efficacy and Antibody Titers during the 2007-2008 Influenza Season

Journal of Infectious Diseases

Volumn 214, Issue 8, 2016, Pages 1142-1149

  Petrie, Joshua G ^a   Ohmit, Suzanne E ^a   Truscon, Rachel ^a   Johnson, Emileigh ^a   Braun, Thomas M ^b   Levine, Min Z ^c   Eichelberger, Maryna C ^d   Monto, Arnold S ^a  

^a Department of Epidemiology ^*  (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antibody persistence; Efficacy; Hemagglutinin; Immune correlates; Influenza; Influenza vaccine; Longevity of antibody; Neuraminidase; Serologic assays; Waning

Indexed keywords

INFLUENZA VACCINE; PLACEBO; SIALIDASE; VIRUS HEMAGGLUTININ; HEMAGGLUTININ; INACTIVATED VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; INCIDENCE; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; ADOLESCENT; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; INFLUENZA; NORMAL HUMAN; ORTHOMYXOVIRIDAE; PROCEDURES; SEASON; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; HUMANS; IMMUNOLOGIC TESTS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; ORTHOMYXOVIRIDAE; SEASONS; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84990924520     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw105     Document Type: Article

References (36)

1. Monto AS. Epidemiology of influenza. Vaccine 2008; 26(suppl 4):D45.-8.
2. Bhatt P, Block SL, Toback SL, Ambrose CS. Timing of the availability and administration of influenza vaccine through the vaccines for children program. Pediatr Infect Dis J 2011; 30:100-6.
3. Toback SL, Herley J, Edelman L, Ambrose CS. Trends in U.S. pediatric influenza vaccination from 2006 to 2010 among children with private insurance. Vaccine 2011; 29:4225-9.
4. Sanofi Pasteur. Sanofi Pasteur ships first 2015-2016 seasonal influenza vaccine doses in United States. http://sanofipasteurus.mediaroom.com/2015-07-14-Sanofi-Pasteur-Ships-First-2015-2016-Seasonal-Influenza-Vaccine-Doses-in-United-States. Accessed 1 September.
5. Centers for Disease Control and Prevention. Past weekly surveillance reports. http://www.cdc.gov/flu/weekly/pastreports.htm. Accessed 1 September.
6. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490-502.
7. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-42.
8. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2014; 63:691-7.
9. Castilla J, Martinez-Baz I, Martinez-Artola V, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013; 18:20388.
10. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013; 18:20390.
11. Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013; 18:20389.
12. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015; 33:246-51.
13. Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010; 29:806-11.
14. Durham LK, Longini IM Jr, Halloran ME, Clemens JD, Nizam A, Rao M. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am J Epidemiol 1998; 147:948-59.
15. Durham LK, Halloran ME, Longini IM Jr, Manatung AK. Comparison of two smoothing methods for exploring waning vaccine effects. J R Stat Soc Ser C Appl Stat 1999; 48:395-407.
16. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-77.
17. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879-85.
18. Couch RB, Atmar RL, Franco LM, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013; 207:974-81.
19. Monto AS, Petrie JG, Cross RT, et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis 2015; 212:1191-9.
20. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-7.
21. Couzens L, Gao J, Westgeest K, et al. An optimized enzyme-linked lectin assay to measure influenza Avirus neuraminidase inhibition antibody titers in human sera. J Virol Methods 2014; 210:7-14.
22. Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect Dis 2015; 212:1914-22.
23. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
24. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
25. Skowronski DM, Janjua NZ, De Serres G, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012; 55:332-42.
26. Sullivan SG, Chilver MB, Higgins G, Cheng AC, Stocks NP. Influenza vaccine effectiveness in Australia: results from the Australian Sentinel Practices Research Network. Med J Aust 2014; 201:109-11.
27. Valenciano M, Ciancio B; team IMs. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill 2012; 17:20281.
28. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
29. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
30. Andrews N, McMenamin J, Durnall H, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill 2014; 19:5-13.
31. Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis 2013; 13:441.
32. Sullivan SG, Komadina N, Grant K, Jelley L, Papadakis G, Kelly H. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. J Med Virol 2014; 86:1017-25.
33. Suzuki M, Minh le N, Yoshimine H, et al. Vaccine effectiveness against medically attended laboratory-confirmed influenza in Japan, 2011-2012 Season. PLoS One 2014; 9:e88813.
34. Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J 2007; 4:42.
35. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis 2015; 211:1529-40.
36. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis 2015; 211:1519-28.